Company intelligence / Profile preview

Signum Dermalogix

Princeton, New Jersey, United Statessignumbiosciences.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Signum Dermalogix has advanced small molecule drug candidates into clinical development for dermatological diseases. Its lead compound DMT‑210 targets multiple inflammatory pathways and has reached Phase 2 trials in atopic dermatitis. The company’s IPC/STM technology platform enables discovery of novel compounds with anti-inflammatory and skin barrier repair properties. An IND was cleared by the FDA for SIG990 as a potential treatment for rosacea.

Therapeutic areas: Dermatology
Modalities: Small moleculesBotanical extracts
Industry: Biotech

Drug pipeline

3 assets

SIG-1459

Pre-clinical

Indications: Skin conditions

2 more assets in the full pipeline.

Request access →

Partnerships

Rohto Pharmaceutical Co., Ltd.HydraFacial

Beyond the preview

Go deeper on Signum Dermalogix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signum Dermalogix.

Explore the full profile